Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sodium gualenate is a water-soluble, small molecule derivative of guaiazulene, a natural azulene compound found in chamomile oil. It is primarily utilized for its anti-inflammatory, cytoprotective, and wound-healing properties. The drug acts by protecting the gastric mucosa, inhibiting the release of histamine from mast cells, and suppressing the emigration of leukocytes to sites of inflammation. Clinically, sodium gualenate is indicated for the treatment of gastric and duodenal ulcers, gastritis, and various inflammatory conditions of the oral and pharyngeal cavities, including stomatitis, pharyngitis, and tonsillitis. It is also formulated for ophthalmic use in treating conjunctivitis and blepharitis, and is incorporated into cosmetic products for its skin-conditioning effects.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sodium gualenate.